clinical-stage drug development company
DeuterOncology has raised €5.7M across 1 funding round from 3 investors, most recently a Series A round in Jan 2023. Based in Liege, Belgium; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2023-01-19 | Series A | €5.7M |
| Investsud Tech,Newton Biocapital,Noshaq |
| View deal → |
